Reviva Other Current Liab from 2010 to 2024

RVPH Stock  USD 1.14  0.02  1.79%   
Reviva Pharmaceuticals' Other Current Liabilities is increasing with slightly volatile movements from year to year. Other Current Liabilities is estimated to finish at about 14 M this year. For the period between 2010 and 2024, Reviva Pharmaceuticals, Other Current Liabilities quarterly trend regression had median of  107,934 and r-value of  0.57. View All Fundamentals
 
Other Current Liabilities  
First Reported
2019-09-30
Previous Quarter
M
Current Value
8.7 M
Quarterly Volatility
M
 
Covid
Check Reviva Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Reviva Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 156.3 K, Tax Provision of 10 K or Net Interest Income of 523.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 22.5. Reviva financial statements analysis is a perfect complement when working with Reviva Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Reviva Pharmaceuticals Correlation against competitors.

Latest Reviva Pharmaceuticals' Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of Reviva Pharmaceuticals Holdings over the last few years. It is Reviva Pharmaceuticals' Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Reviva Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Slightly volatile
   Other Current Liab   
       Timeline  

Reviva Other Current Liab Regression Statistics

Arithmetic Mean1,853,873
Coefficient Of Variation259.96
Mean Deviation3,148,049
Median107,934
Standard Deviation4,819,267
Sample Variance23.2T
Range15M
R-Value0.57
Mean Square Error16.8T
R-Squared0.33
Significance0.03
Slope617,820
Total Sum of Squares325.2T

Reviva Other Current Liab History

202414 M
202313.3 M
2022-1 M
20211.3 M
2020-683.3 K
2019-123 K

About Reviva Pharmaceuticals Financial Statements

Investors use fundamental indicators, such as Reviva Pharmaceuticals' Other Current Liab, to determine how well the company is positioned to perform in the future. Although Reviva Pharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Other Current Liabilities13.3 M14 M

Currently Active Assets on Macroaxis

When determining whether Reviva Pharmaceuticals is a strong investment it is important to analyze Reviva Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Reviva Pharmaceuticals' future performance. For an informed investment choice regarding Reviva Stock, refer to the following important reports:
Check out the analysis of Reviva Pharmaceuticals Correlation against competitors.
You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Reviva Pharmaceuticals. If investors know Reviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Reviva Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.08)
Return On Assets
(2.34)
Return On Equity
(17.95)
The market value of Reviva Pharmaceuticals is measured differently than its book value, which is the value of Reviva that is recorded on the company's balance sheet. Investors also form their own opinion of Reviva Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reviva Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Reviva Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reviva Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Reviva Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Reviva Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Reviva Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.